


PHARMACEUTICAL 2020

MyoKardia Inc. Rank 230 of 362





PHARMACEUTICAL 2020

MyoKardia Inc. Rank 230 of 362

The relative strengths and weaknesses of MyoKardia Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyoKardia Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 231% points. The greatest weakness of MyoKardia Inc. is the variable Net Income, reducing the Economic Capital Ratio by 170% points.

The company's Economic Capital Ratio, given in the ranking table, is -266%, being 37% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	423,836
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	47,912
Liabilities, Non-Current	1,908
Other Assets	16,515
Other Compr. Net Income	616
Other Expenses	80,000
Other Liabilities	0
Other Net Income	11,621
Property and Equipment	15,743
Research and Development	146,171
Revenues	0
Selling, General and Administrative Expense	61,663

Output Variable	Value in 1000 USD
Assets	456,094
Liabilities	49,820
Expenses	287,834
Stockholders Equity	406,274
Net Income	-276,213
Comprehensive Net Income	-275,905
Economic Capital Ratio	-266%